DC4U B.V.
 |
DC4U B.V. Year of foundation: 2006 |
Company Profile
DC4U B.V. aims to develop therapeutic and diagnostic tools for cancer. The company owns the exclusive worldwide license for all existing and all future IP in the field of glycoproteins and glycosylation processes involved in immune signalling, for use in the development of vaccines or therapeutics or diagnostics in the areas of infectious diseases, immunological disorders and cancer. DC4U B.V. has a strong team with scientific, legal, financial, commercial, IP and licensing expertise.Science and Technologies or Services
Recently, glycomics research has yielded potential leads that may provide innovative solutions for the treatment of cancer. Glycomics is a new biomedical discipline that investigates how sugar modification of macromolecules (glycosylation) affects their biological and pathological function. Recent exciting discoveries in this field, in which Prof. Dr. Y. van Kooyk has a world-leading role, are further explored. DC4U B.V. strongly believes that liposomes containing highly specific APC-targeting signals using glycans provide the answer in the search for a new vaccine to cure colon cancer. The fact that certain glycans can target two different APC subsets allows us for the first time to design a vaccine that targets both subsets that have strong immune-modulating capacity.
Alliances
- Drug Discovery Factory B.V.
- VU Medical Center Amsterdam
- Octoplus Technologies B.V.
- Utrecht University
- Technical University Munchen
Keywords
- Cancer
- Therapeutics
- Vaccines
- Immunotherapy
- Autoimmunity
- Dendritic Cells
- Drug Discovery
